Effect of Quetiapine on negative symptoms and cognition

Study identifier:5077/9007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of Quetiapine compared to Risperidone on negative symptoms and cognition with regard to underlying neurobiological mechanisms and brain activation.

Medical condition

schizophrenia

Phase

Phase 3

Healthy volunteers

Study drug

Quetiapine fumarate, Risperidone

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2001

Primary Completion Date: -

Study Completion Date: 01 Jan 2003

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Munich, Germany

Arms	Assigned Interventions

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca GmbH

+49 4103 708 0

Investigators

Principal Investigator

AstraZeneca Germany Medical Director

AstraZeneca